Hosted on MSN1d
Wolfe Research Downgrades Matson (MATX)
Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...
Fintel on MSN3d
Wolfe Research Initiates Coverage of Eli Lilly and (LLY) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Wolfe Research starts Moderna at Underperform, sees limited upside opportunity
Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...
Matson downgraded at Wolfe on potential tariff risk, lower ocean rates
Matson downgraded at Wolfe Research, expecting demand risk from China tariffs and lower ocean rates after shares outperformed this year.
bovnews1d
Why Did Wolfe Research Give Gilead Sciences, Inc. (GILD) Stock Outperform Rating?
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
Investing4d
Wolfe Research sets stock target on Veracyte, cites growth potential
On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...
Nasdaq4d
Wolfe Research Initiates Coverage of AbbVie (SNSE:ABBVCL) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (SNSE:ABBVCL) with a Outperform recommendation. What is the Fund Sentiment? There are 4,922 funds or ...
Seeking Alpha4d
U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement "Make America Healthy Again," championed by Robert F.
Nasdaq4d
Wolfe Research starts BioMarin at Outperform given its blockbuster with Voxzogo
Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following recent share pullback, a new management team, and robust ...
bovnews4d
Wolfe Research Just Resumed ConocoPhillips (COP) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...
Investing4d
Wolfe Research sets stock target on Veracyte, cites growth potential
On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte's ...